Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib; Bortezomib; Carfilzomib; Dexamethasone
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- Acronyms ENDURANCE
- 07 Dec 2017 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2023.
- 13 Oct 2017 Planned primary completion date changed from 1 May 2016 to 1 Nov 2024.
- 04 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.